Clinical Trial: A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients with Dravet Syndrome

U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT06872125) titled 'A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients with Dravet Syndrome' on March 06.

Brief Summary: The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Dravet Syndrome

Intervention: DRUG: zorevunersen

Zorevunersen group will receive study drug by intrathecal (IT) administration on Day 1 (after the 8-week Baseline Period), Day 57 (Week 8), Day 169 (Week 24), and Day 281 (Week 40) at a dose level of 70 mg on Day 1 and Day 57, and 45 mg o...